Llama immunization with full-length VAR2CSA generates cross-reactive and inhibitory single-domain antibodies against the DBL1X domain

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Nunes Silva, Sofia ^a,b,c,d   Gangnard, Stéphane ^a,b,c,d   Vidal, Marta ^a,b,c,d   Vuchelen, Anneleen ^e,f   Dechavanne, Sebastien ^a,b,c,d   Chan, Sherwin ^g   Pardon, Els ^e,f   Steyaert, Jan ^e,f   Ramboarina, Stephanie ^e,f   Chêne, Arnaud ^a,b,c,d   Gamain, Benoît ^a,b,c,d  

^a INSERM   (France)

^b hôpital Robert Debré et Institut national de la transfusion sanguine   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^d Laboratory of Excellence GR Ex   (France)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NANOBODY; PARASITE ANTIGEN; PROTEIN BINDING; RECOMBINANT PROTEIN; VAR2CSA PROTEIN, PLASMODIUM FALCIPARUM;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CROSS REACTION; EPITOPE MAPPING; ERYTHROCYTE; FEMALE; HUMAN; IMMUNIZATION; IMMUNOLOGY; KINETICS; MOLECULAR GENETICS; NEW WORLD CAMELID; PARASITOLOGY; PLACENTA; PREGNANCY; PROTEIN CONFORMATION; PROTEIN DOMAIN; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, PROTOZOAN; CAMELIDS, NEW WORLD; CROSS REACTIONS; EPITOPE MAPPING; EPITOPES; ERYTHROCYTES; FEMALE; HUMANS; IMMUNIZATION; KINETICS; MOLECULAR SEQUENCE DATA; PLACENTA; PREGNANCY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SINGLE-DOMAIN ANTIBODIES;

EID: 84921801545     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07373     Document Type: Article

References (49)

1. World Malaria Report 2013. World Health Organization, Geneva, Switzerland. ISBN: 9 789241 56469 4 (2013).
2. Miller, L. H., Baruch, D. I., Marsh, K. & Doumbo, O. K. The pathogenic basis of malaria. Nature 415, 673-679, doi:10.1038/415673a415673a (2002).
3. Barnwell, J. W., Howard, R. J. & Miller, L. H. Influence of the spleen on the expression of surface antigens on parasitized erythrocytes. Ciba Found Symp 94, 117-136 (1983).
4. Buffet, P. A. et al. The pathogenesis of Plasmodiumfalciparummalaria in humans: insights from splenic physiology. Blood 117, 381-392, doi:10.1182/blood-2010-04-202911blood-2010-04-202911 (2011).
5. Smith, J. D. et al. Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82, 101-110, doi:0092-8674(95)90056-X (1995).
6. Baruch, D. I. et al. Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82, 77-87, doi:0092-8674(95)90054-3 (1995).
7. Smith, J. D., Rowe, J. A., Higgins, M. K. & Lavstsen, T. Malaria's deadly grip: cytoadhesion of Plasmodium falciparum-infected erythrocytes. Cell Microbiol 15, 1976-1983, doi:10.1111/cmi.12183 (2013).
8. McGregor, I. A. Immunity and malaria in man. Trop Doct 4, 104-109 (1974).
9. Walter, P. R., Garin, Y. & Blot, P. Placental pathologic changes in malaria. A histologic and ultrastructural study. Am J Pathol 109, 330-342 (1982).
10. Umbers, A. J., Aitken, E. H. & Rogerson, S. J. Malaria in pregnancy: small babies, big problem. Trends Parasitol 27, 168-175, doi:10.1016/j.pt.2011.01.007S1471-4922(11)00020-1 (2011).
11. Desai, M. et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7, 93-104, doi:S1473-3099(07)70021-X (2007).
12. Beeson, J. G. et al. Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. J Infect Dis 180, 464-472, doi:JID981531 (1999).
13. Fried, M. & Duffy, P. E. Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 272, 1502-1504 (1996).
14. Agbor-Enoh, S. T. et al. Chondroitin sulfate proteoglycan expression and binding of Plasmodium falciparum-infected erythrocytes in the human placenta during pregnancy. Infect Immun 71, 2455-2461 (2003).
15. Doritchamou, J. et al. First-trimester Plasmodium falciparum infections display a typical "placental" phenotype. J Infect Dis 206, 1911-1919, doi:10.1093/infdis/jis629jis629 (2012).
16. Fried, M., Nosten, F., Brockman, A., Brabin, B. J. & Duffy, P. E. Maternal antibodies block malaria. Nature 395, 851-852, doi:10.1038/27570 (1998).
17. Viebig, N. K. et al.Disruption of var2csa gene impairs placentalmalaria associated adhesion phenotype. PLoS One 2, e910, doi:10.1371/journal.pone.0000910 (2007).
18. Viebig, N. K. et al. A single member of the Plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A. EMBO Rep 6, 775-781, doi:7400466 (2005).
19. Salanti, A. et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200, 1197-1203, doi:jem.20041579 (2004).
20. Salanti, A. et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 49, 179-191, doi:3570 (2003).
21. Bockhorst, J. et al. Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA. Mol Biochem Parasitol 155, 103-112, doi:S0166-6851(07)00163-6 (2007).
22. Srivastava, A. et al. Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA. Proc Natl Acad Sci U S A 107, 4884-4889, doi:10.1073/pnas.10009511071000951107 (2010).
23. Khunrae, P. et al. Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies. J Mol Biol 397, 826-834, doi:10.1016/j.jmb.2010.01.040S0022-2836(10)00086-0 (2010).
24. Srivastava, A. et al. Var2CSA minimal CSA binding region is located within the N-terminal region. PLoS One 6, e20270, doi:10.1371/journal.pone.0020270PONE-D-11-03862 (2011).
25. Clausen, T. M. et al. Structural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria. J Biol Chem 287, 23332-23345, doi:10.1074/jbc.M112.348839M112.348839 (2012).
26. Bigey, P. et al. The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. J Infect Dis 204, 1125-1133, doi:10.1093/infdis/jir499jir499 (2011).
27. Bordbar, B. et al. Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. Vaccine 30, 1343-1348, doi:10.1016/j.vaccine.2011.12.065S0264-410X(11)02003-2 (2012).
28. Doritchamou, J. et al. Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. Vaccine 31, 4516-4522, doi:10.1016/j.vaccine.2013.07.072S0264-410X(13)01058-X (2013).
29. Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82, 775-797, doi:10.1146/annurev-biochem-063011-092449 (2013).
30. Adams, H. et al. Specific immuno capturing of the staphylococcal superantigen toxic-shock syndrome toxin-1 in plasma. Biotechnol Bioeng 104, 143-151, doi:10.1002/bit.22365 (2009).
31. Tereshko, V. et al. Toward chaperone-assisted crystallography: protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (VHH) scaffold. Protein Sci 17, 1175-1187, doi:10.1110/ps.034892.108ps.034892.108 (2008).
32. Park, Y. J., Pardon, E., Wu, M., Steyaert, J. & Hol, W. G. Crystal structure of a heterodimer of editosome interaction proteins in complex with two copies of a cross-reacting nanobody. Nucleic Acids Res 40, 1828-1840, doi:10.1093/nar/gkr867gkr867 (2012).
33. Rasmussen, S. G. et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477, 549-555, doi:10.1038/nature10361nature10361 (2011).
34. Rahbarizadeh, F., Ahmadvand, D. & Sharifzadeh, Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol Invest 40, 299-338, doi:10.3109/08820139.2010.542228 (2011).
35. Muyldermans, S. Single domain camel antibodies: current status. J Biotechnol 74, 277-302, doi:S1389-0352(01)00021-6 (2001).
36. Habib, I. et al. V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays. Anal Biochem 438, 82-89, doi:10.1016/j.ab.2013.03.020S0003-2697(13)00140-1 (2013).
37. Dahlback, M. et al. The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains. J Biol Chem 286, 15908-15917, doi:10.1074/jbc.M110.191510M110.191510 (2011).
38. Ditlev, S. B. et al. Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA. PLoS One 9, e84981, doi:10.1371/journal.pone.0084981PONE-D-13-40830 (2014).
39. Gamain, B. et al. Identification of multiple chondroitin sulfate A (CSA)-binding domains in the var2CSA gene transcribed in CSA-binding parasites. J Infect Dis 191, 1010-1013, doi:JID33609 (2005).
40. Rasti, N. et al. Nonimmune immunoglobulin binding and multiple adhesion characterize Plasmodium falciparum-infected erythrocytes of placental origin. Proc Natl Acad Sci U S A 103, 13795-13800, doi:0601519103 (2006).
41. Tutterrow, Y. L. et al. High avidity antibodies to full-length VAR2CSA correlate with absence of placental malaria. PLoS One 7, e40049, doi:10.1371/journal.pone.0040049PONE-D-12-09930 (2012).
42. Magistrado, P. A. et al. High efficacy of anti DBL4varepsilon-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women. Vaccine 29, 437-443, doi:10.1016/j.vaccine.2010.10.080S0264-410X(10)01593-8 (2011).
43. De Genst, E. et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A 103, 4586-4591, doi:0505379103 (2006).
44. Hassanzadeh-Ghassabeh, G., Saerens, D. & Muyldermans, S. Generation of anti-infectome/anti-proteome nanobodies. Methods Mol Biol 790, 239-259, doi:10.1007/978-1-61779-319-6-19 (2011).
45. Pardon, E. et al. Ageneral protocol for the generation of Nanobodies for structural biology. Nat Protoc 9, 674-693, doi:10.1038/nprot.2014.039nprot.2014.039 (2014).
46. Trager, W. & Jensen, J. B. Humanmalaria parasites in continuous culture. Science 193, 673-675 (1976).
47. Viebig, N. K., Nunes, M. C., Scherf, A. & Gamain, B. The human placental derived BeWo cell line: a useful model for selecting Plasmodium falciparum CSA-binding parasites. Exp Parasitol 112, 121-125, doi:S0014-4894(05)00233-X (2006).
48. Snounou, G. et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93, 369-374 (1999).
49. Staalsoe, T., Giha, H. A., Dodoo, D., Theander, T. G. & Hviid, L. Detection of antibodies to variant antigens on Plasmodium falciparum-infected erythrocytes by flow cytometry. Cytometry 35, 329-336, doi:10.1002/(SICI)1097-0320(19990401)35:4〈329::AID-CYTO5〉3.0.CO;2-Y (1999).